Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

NCT05616390 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Sintilimab
DRUG: Bevacizumab
COMBINATION_PRODUCT: Liver Protective Support Therapy

Sponsor

Tianjin Medical University Cancer Institute and Hospital